MCID: LNG111
MIFTS: 34

Lung Non-Squamous Non-Small Cell Carcinoma

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Lung Non-Squamous Non-Small Cell Carcinoma

MalaCards integrated aliases for Lung Non-Squamous Non-Small Cell Carcinoma:

Name: Lung Non-Squamous Non-Small Cell Carcinoma 12
Non- Squamous Nsclc 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0080521
NCIt 49 C135017

Summaries for Lung Non-Squamous Non-Small Cell Carcinoma

Disease Ontology : 12 A lung non-small cell carcinoma that is characterized by the lack of evidence of squamous differentiation.

MalaCards based summary : Lung Non-Squamous Non-Small Cell Carcinoma, also known as non- squamous nsclc, is related to lung cancer susceptibility 3 and pulmonary hypertension. The drugs Carboplatin and Docetaxel have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and brain.

Related Diseases for Lung Non-Squamous Non-Small Cell Carcinoma

Diseases related to Lung Non-Squamous Non-Small Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 lung cancer susceptibility 3 10.1
2 pulmonary hypertension 10.0
3 exanthem 10.0
4 congestive heart failure 10.0

Symptoms & Phenotypes for Lung Non-Squamous Non-Small Cell Carcinoma

Drugs & Therapeutics for Lung Non-Squamous Non-Small Cell Carcinoma

Drugs for Lung Non-Squamous Non-Small Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 118)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 4 41575-94-4 10339178 498142 38904
2
Docetaxel Approved, Investigational Phase 4 114977-28-5 148124
3
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
4
nivolumab Approved Phase 3 946414-94-4
5
Ipilimumab Approved Phase 3 477202-00-9
6
Crizotinib Approved Phase 3 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
7
Cemiplimab Approved, Investigational Phase 3 1801342-60-8
8
Osimertinib Approved Phase 3 1421373-65-0 71496458
9
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
10
leucovorin Approved Phase 3 58-05-9 6006 143
11
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 60843 446556
12
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
13
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
14
Imetelstat Investigational Phase 3 868169-64-6
15 Pharmaceutical Solutions Phase 3
16 Immunoglobulin G Phase 3
17 Endothelial Growth Factors Phase 3
18
s 1 (combination) Phase 3
19 Folic Acid Antagonists Phase 3
20 Vitamin B Complex Phase 3
21 Vitamin B9 Phase 3
22 Protein Kinase Inhibitors Phase 3
23 Folate Phase 3
24 Mitogens Phase 3
25
Erlotinib Hydrochloride Phase 3 183319-69-9 176871
26 Albumin-Bound Paclitaxel Phase 3
27
Motesanib diphosphate Phase 3 850649-62-6 11450633
28
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
29
Nitroglycerin Approved, Investigational Phase 2 55-63-0 4510
30
Nintedanib Approved Phase 2 656247-17-5 56843413
31
Axitinib Approved, Investigational Phase 1, Phase 2 319460-85-0 6450551
32
Ceritinib Approved Phase 2 1032900-25-6
33
Gemcitabine Approved Phase 2 95058-81-4 60750
34
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
35
Etoposide Approved Phase 2 33419-42-0 36462
36
Acyclovir Approved Phase 2 59277-89-3 2022
37
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
38
Methylcobalamin Approved, Investigational Phase 2 13422-55-4
39
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
40
Hydroxocobalamin Approved Phase 2 13422-51-0 11953898 15589840
41
ramucirumab Approved, Investigational Phase 2 947687-13-0
42
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
43
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
44
Olaparib Approved Phase 2 763113-22-0 23725625
45
Durvalumab Approved, Investigational Phase 2 1428935-60-7
46
Talazoparib Approved, Investigational Phase 2 1207456-01-6 135565082
47
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
48
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
49
Trametinib Approved Phase 2 871700-17-3 11707110
50
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639

Interventional clinical trials:

(show top 50) (show all 161)
# Name Status NCT ID Phase Drugs
1 Phase IV/II Open-label Study to Evaluate Prompt Response to Treatment With Cisplatin, Gemcitabine and Bevacizumab in Patients With Non-small Lung Cancer. Completed NCT02316327 Phase 4 gemcitabine, cisplatin and bevacizumab
2 A Study to Evaluate the Efficacy and Safety of Anlotinib Plus Pemetrexed as the 1-line Treatment of Patients With Platinum Intolerant Advanced Non-squamous NSCLC, With Pemetrexed Control. Recruiting NCT03768037 Phase 4 Anlotinib plus Pemetrexed;Pemetrexed
3 An Open, Single-arm, Multi-center Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy Not yet recruiting NCT03778853 Phase 4 Anlotinib Hydrochloride
4 An Open, Single-arm, Multi-center Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line Chemotherapy Not yet recruiting NCT03755869 Phase 4 Anlotinib
5 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Not yet recruiting NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
6 Efficacy and Safety Evaluation of IBI308 Versus Docetaxel in Patients With Advanced or Metastatic Squamous Cell Lung Cancer After Failure of First-line Platinum-based Therapy- a Randomized, Open-label, Multicenter, Parallel, Phase 3 Study (ORIENT-3) Unknown status NCT03150875 Phase 3 Docetaxel
7 A Factorial Study Comparing Pemetrexed With Gemcitabine and Testing the Efficacy of the Addition of Cisplatin in Elderly Patients With Non Squamous Advanced, Metastatic or Recurrent NSCLC. Unknown status NCT01656551 Phase 3 Gemcitabine;Pemetrexed;Cisplatin
8 A Randomized, Open-label, Phase III Study Comparing Pemetrexed With and Without Carboplatin in Elderly Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Unknown status NCT01593293 Phase 3 PemCarbo;Pem only
9 Randomized Phase II/III Adjuvant Trial Evaluating Feasibility of Standard (A) vs. Customized Treatment (B) in Stage II or Stage IIIA Non-N2, Non-squamous Non Small Cell Lung Cancer (NSCLC). Completed NCT00775385 Phase 2, Phase 3 Standard Chemotherapy;Customized Treatment
10 A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF- 06439535 PLUS PACLITAXEL-CARBOPLATIN AND BEVACIZUMAB PLUS PACLITAXEL -CARBOPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER. Completed NCT02364999 Phase 3 Bevacizumab-Pfizer;Bevacizumab-EU;Paclitaxel;Carboplatin
11 A Randomized, Double-blind Study of the Effect of Avastin Plus Cisplatin and Gemcitabine or Placebo Plus Cisplatin and Gemcitabine on Progression-free Survival in Treatment-naïve Patients With Advanced or Recurrent Non-squamous NSCLC Completed NCT00806923 Phase 3 Cisplatin;Gemcitabine;Placebo;bevacizumab [Avastin];bevacizumab [Avastin]
12 International Multicenter Randomized Double Blind Phase III Trial Comparing Safety and Efficacy of BCD-021 (CJSC BIOCAD, Russia) and Paclitaxel + Carboplatin to Avastin® (F. Hoffmann-La Roche Ltd, Switzerland) and Paclitaxel + Carboplatin in Inoperable or Advanced Non-squamous Non-small-cell Lung Cancer (NSCLC) Patients Completed NCT01763645 Phase 3 Bevacizumab;Paclitaxel;Carboplatin
13 An Open-label, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression of Disease (PD) in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) After First Line Treatment With Bevacizumab Plus a Platinum Doublet-containing Chemotherapy Completed NCT01351415 Phase 3 Bevacizumab;Docetaxel;Erlotinib;Pemetrexed
14 Open-label Study of Bevacizumab (Avastin®) in Combination With Pemetrexed or Pemetrexed and Carboplatin as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer Completed NCT00976456 Phase 3 Bevacizumab + Pemetrexed;Bevacizumab + Pemetrexed + Carboplatin
15 A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Clinical Trial in Patients With Advanced Non-squamous Non-small Cell Lung Cancer Treated With Fruquintinib Completed NCT02691299 Phase 3 Fruquintinib;Placebo
16 EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis Recruiting NCT03793179 Phase 3 Carboplatin;Pemetrexed
17 A Two-Part Randomized, Phase 3 Study of Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in First-line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Recruiting NCT03409614 Phase 3 REGN2810;REGN2810/chemo/ipi;Placebo
18 Efficacy and Safety of First-line MIL60 Plus Paclitaxel/Carboplatin Versus Bevacizumab Plus Paclitaxel/Carboplatin in Patients With Advanced and Recurrent Non-squamous Non-small Cell Lung Cancer: a Randomized, Double-blind, Phase 3 Study Recruiting NCT03196986 Phase 3 MIL60;Bevacizumab
19 A Randomized, Double-blind, Multi-center, Phase III Clinical Study Assessing the Efficacy and Safety of Sintilimab ± IBI305 Combined With Pemetrexed and Cisplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Failed Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (ORIENT-31) Recruiting NCT03802240 Phase 3 Sintilimab;IBI305;Pemetrexed;Cisplatin;Placebo1;Placebo2
20 Randomized, Open Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non- Squamous Non-Small Cell Lung Cancer Patients With CEACAM5 Positive Tumors Recruiting NCT04154956 Phase 3 SAR408701;docetaxel
21 Observational Clinical Trial of Adjuvant Chemotherapy for Non-squamous Cell Carcinoma of Non-small Cell Lung Cancer Recruiting NCT03656393 Phase 3 Gefitinib;Vinorelbine;Carboplatin
22 A Phase III, Randomized, Open-Label, Multi-center Study of SHR-1210(Anti-PD-1 Antibody) in Combination With Pemetrexed and Carboplatin as First Line Therapy in Subjects With Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer Recruiting NCT03134872 Phase 3 Carboplatin;Pemetrexed
23 A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy in Combination With Checkpoint Inhibitor Therapy Recruiting NCT03906071 Phase 3 Sitravatinib;Docetaxel
24 PD-(L)1 Inhibitors With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer Recruiting NCT03774732 Phase 3 Anti-PD(L)-1
25 A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Tumors Expressing PD-L1 ≥50% Active, not recruiting NCT03515629 Phase 3 REGN2810/ipi;REGN2810/chemo/ipi;Pembrolizumab
26 A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin® In 1st Line Treatment for Patients With Advanced/Recurrent Non Squamous NSCLC in Combination of Paclitaxel and Carboplatin Active, not recruiting NCT02810457 Phase 3 FKB238 (bevacizumab);Avastin (bevacizumab);Paclitaxel;Carboplatin
27 Study to Evaluate the Efficacy and Safety of IBI305 in Combination With Paclitaxel/Carboplatin Versus Bevacizumab in Combination With Paclitaxel/Carboplatin in Treatment-naïve Patients With Advanced or Recurrent Non-squamous NSCLC Active, not recruiting NCT02954172 Phase 3 Bevacizumab in combination with Paclitaxel/Carboplatin;Avastin in combination with Paclitaxel/Carboplatin
28 A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting NCT03296163 Phase 3 MB02 (Bevacizumab Biosimilar Drug);EU-approved Avastin®;Carboplatin;Paclitaxel
29 A Phase III Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting NCT02367781 Phase 3 Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody;Carboplatin;Nab-Paclitaxel;Pemetrexed
30 A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting NCT02366143 Phase 3 Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody;Bevacizumab;Carboplatin;Paclitaxel
31 A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting NCT02657434 Phase 3 Atezolizumab;Carboplatin;Cisplatin;Pemetrexed
32 Randomized Phase III Study of Maintenance Therapy With Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC Active, not recruiting NCT01107626 Phase 3 pemetrexed disodium
33 PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED EAST ASIAN PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS Active, not recruiting NCT01639001 Phase 3 Crizotinib;Pemetrexed/Cisplatin;Pemetrexed/Carboplatin
34 Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Not yet recruiting NCT04181060 Phase 3 Osimertinib
35 A Randomized, Double-blinded, Phase III Study of Pemetrexed Plus Platinum Chemotherapy With or Without Sintilimab (IBI308) in First Line Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (Orient-11) Not yet recruiting NCT03607539 Phase 3 Sintilimab;Pemetrexed;Platinum;Placebos
36 Clinical Research of S-1 Versus Pemetrexed in the Maintenance Treatment of Advanced Non-squamous Non-small Cell Lung Cancer Not yet recruiting NCT03700333 Phase 3 S-1 therapy;Pemetrexed therapy
37 International Multicenter Randomized Double-Blind Placebo-Controlled Clinical Trial Evaluating Efficacy and Safety Of BCD-100 in Combination With Pemetrexed+Cisplatin/Carboplatin Compared to Placebo in Combination With Pemetrexed+Cisplatin/Carboplatin as First-Line Treatment of Subjects With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) Not yet recruiting NCT03912389 Phase 3 Pemetrexed;Cisplatin (or carboplatin)
38 A Three Arm, Randomized, Double-Blind, Multicenter, Phase 3 Study of HLX10(Anti-PD-1 Antibody) in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04(Avastin Biosimilar) Compared With Carboplatin+Pemetrexed in 1L Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Not yet recruiting NCT03952403 Phase 3 HLX10, an engineered anti-PD-1 antibody;HLX04, a bevacizumab biosimilar;Carboplatin;Pemetrexed
39 A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non-small Cell Lung Cancer. Terminated NCT00460317 Phase 3 AMG 706;placebo;paclitaxel;carboplatin
40 A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Subjects With Locally Advanced or Metastatic, Non-Squamous, Non-Small-Cell Lung Cancer With Wild-type Epidermal Growth Factor Receptor Terminated NCT01377376 Phase 3 ARQ 197 and Erlotinib;Placebo and Erlotinib
41 Multicentre, Randomised, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral SHR1020 Plus Docetaxel Therapy Compared to Placebo Plus Docetaxel Therapy in Patients With Local Advanced or Metastatic or Recurrent Non Squamous Non Small Cell Lung Cancer After Failure of First Line Chemotherapy. Terminated NCT02766140 Phase 3 SHR1020 plus Docetaxel;Placebo plus Docetaxel
42 A Randomized Phase III Study of Docetaxel Versus Intercalated Erlotinib Docetaxel Combination Therapy in Patients With Relapsed EGFR (Epidermal Growth Factor Receptor) Wild Type, ALK(Anaplastic Lymphoma Kinase) Negative Non Squamous Cell Carcinoma. (NVALT 18 Study) Terminated NCT02775006 Phase 3 Docetaxel;Erlotinib
43 Maintenance Pemetrexed Therapy After Induction Chemotherapy Versus Pemetrexed at Progression in Advanced Non-Small-Cell Lung Cancer: A Randomized Phase III Study Terminated NCT02004184 Phase 3 maintenance pemetrexed;pemetrexed at progression
44 Icotinib Combined With Stereotactic Body Radiation Therapy (SBRT) for Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Sensitive Mutation Unknown status NCT03153358 Phase 2 Icotinib
45 An Open-label Randomized Phase II Trial of Gemcitabine and Cisplatin With or Without Bevacizumab in EGFR Wild-type Non-squamous Non-small-cell Lung Cancer Patients Unknown status NCT01623102 Phase 2 cisplatin and gemcitabine combination with Bevacizumab;Gemcitabine combined with cisplatin chemotherapy
46 A Randomized Phase II Study of Paclitaxel-carboplatin-bevacizumab With or Without Nitroglycerin Patches in Patients With Stage IV Non-squamous-non-small Cell Lung Cancer: NVALT12 Unknown status NCT01171170 Phase 2 carboplatin paclitaxel bevacizumab;Standard treatment plus nitroglycerin
47 Randomized Phase II Trial of Three-weekly Cisplatinum and Pemetrexed Versus Split-dose d1 and d8 Cisplatinum and Pemetrexed In Advanced and Inoperable Non-squamous Non-small-cell Lung Cancer (NSCLC) Unknown status NCT01742767 Phase 2 Cisplatinum;Pemetrexed
48 A Randomized Phase II Study of Erlotinib Compared to Single Agent Chemotherapy-erlotinib Combination in Pretreated Patients With Advanced NSCLC (NVALT10 Study) Unknown status NCT00835471 Phase 2 erlotinib plus docetaxel or pemetrexed;erlotinib
49 A Randomized Phase II Trial of Carboplatin-Paclitaxel Compared to Carboplatin-Paclitaxel-Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer Unknown status NCT01770171 Phase 2 Bevacizumab;Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles
50 An Open-labeled, Single Arm, Multicenter Phase II Study to Evaluate Efficacy and Safety of Bevacizumab Plus Chemotherapy for Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer With EGFR-TKI Resistance Unknown status NCT02139579 Phase 2 Bevacizumab

Search NIH Clinical Center for Lung Non-Squamous Non-Small Cell Carcinoma

Genetic Tests for Lung Non-Squamous Non-Small Cell Carcinoma

Anatomical Context for Lung Non-Squamous Non-Small Cell Carcinoma

MalaCards organs/tissues related to Lung Non-Squamous Non-Small Cell Carcinoma:

40
Lung, Testes, Brain, Endothelial, Bone, Lymph Node, Thyroid

Publications for Lung Non-Squamous Non-Small Cell Carcinoma

Articles related to Lung Non-Squamous Non-Small Cell Carcinoma:

(show top 50) (show all 327)
# Title Authors PMID Year
1
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer. 61
31671314 2019
2
Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations. 61
31829747 2019
3
Evaluation of PAP in EGFR Mutational Testing in Advanced NSCLC: a Comparative Study. 61
31710424 2019
4
New options for combination therapy for advanced non-squamous NSCLC. 61
31512526 2019
5
A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients. 61
31493177 2019
6
Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis. 61
31835042 2019
7
The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706). 61
31699150 2019
8
Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial. 61
31703637 2019
9
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. 61
31752994 2019
10
The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients. 61
31709742 2019
11
Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study. 61
31655564 2019
12
PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study. 61
31338773 2019
13
The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients. 61
30953094 2019
14
Predictive and Prognostic Value of 18F-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer. 61
31434972 2019
15
Pemetrexed Induced Life-threatening Anaphylaxis. 61
31687290 2019
16
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer. 61
31332704 2019
17
Exceptional pemetrexed sensitivity can predict therapeutic benefit from subsequent chemotherapy in metastatic non-squamous non-small cell lung cancer. 61
31144157 2019
18
Survival Disparities in Black Patients With EGFR-mutated Non-small-cell Lung Cancer. 61
31420240 2019
19
A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC. 61
31231786 2019
20
Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab. 61
31186697 2019
21
An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer. 61
31092443 2019
22
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. 61
30975627 2019
23
Treatment patterns, duration and outcomes of pemetrexed maintenance therapy in patients with advanced NSCLC in a real-world setting. 61
30421624 2019
24
AVAiLABLE NIS - AVASTIN® in lung cancer treatment in routine oncology practice in Germany. 61
31077164 2019
25
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. 61
30954906 2019
26
Impact of EGFR Mutation and ALK Translocation on Recurrence Pattern After Definitive Chemoradiotherapy for Inoperable Stage III Non-squamous Non-small-cell Lung Cancer. 61
30926356 2019
27
Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer. 61
30940113 2019
28
Treatment Decisions for Advanced Non-Squamous Non-Small Cell Lung Cancer: Patient and Physician Perspectives on Maintenance Therapy. 61
30128728 2019
29
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. 61
30797489 2019
30
Co-alteration of EGFR mutation and ALK rearrangement in non-small cell lung cancer: Case series. 61
30817606 2019
31
Real-World Data of the Correlation between EGFR Determination by Liquid Biopsy in Non-squamous Non-small Cell Lung Cancer (NSCLC) and the EGFR Profile in Tumor Biopsy. 61
30847713 2019
32
Phase I dose escalation study of pemetrexed and concurrent thoracic radiation in elderly patients with non-squamous non-small-cell lung cancer. 61
30496584 2019
33
The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer. 61
30778772 2019
34
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. 61
30736848 2019
35
Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France. 61
30642550 2019
36
Pemetrexed and carboplatin combination therapy followed by pemetrexed maintenance in Japanese patients with non-squamous non-small cell lung cancer: A subgroup analysis of elderly patients. 61
30293944 2019
37
Neutrophil-To-Lymphocyte Ratio Predicted Long-Term Chemotherapy Benefits In Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer Patients Without Sensitive Mutations. 61
31695433 2019
38
Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability. 61
30973926 2019
39
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations. 61
30377342 2019
40
The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer. 61
30354693 2018
41
A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101). 61
30027464 2018
42
Incomplete uptake of EGFR mutation testing and its impact on estimation of mutation prevalence in patients with non-squamous NSCLC: A population-based study in New Zealand. 61
30278336 2018
43
Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US. 61
30188231 2018
44
[National variation in molecular diagnostics in metastatic lung cancer]. 61
30570921 2018
45
The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictions. 61
30477516 2018
46
A Phase IV Efficacy Study of Formeta Plus Carboplatin as First-Line Treatment of Advanced Non-Squamous, Non-Small Cell Lung Cancer in Iran: An Affordable Price with Clinical Benefit 61
30362335 2018
47
Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057. 61
30103096 2018
48
The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics. 61
29535211 2018
49
Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations. 61
29101518 2018
50
Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy. 61
30032838 2018

Variations for Lung Non-Squamous Non-Small Cell Carcinoma

Cosmic variations for Lung Non-Squamous Non-Small Cell Carcinoma:

9 (show top 50) (show all 17775)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM98616023 ZZEF1 lung,NS,carcinoma,small cell carcinoma c.4892G>T p.G1631V 17:4059282-4059282 9
2 COSM86240454 ZYG11B lung,NS,carcinoma,small cell carcinoma c.1635G>C p.M545I 1:52801968-52801968 9
3 COSM86919234 ZSWIM4 lung,NS,carcinoma,small cell carcinoma c.944G>T p.R315L 19:13809152-13809152 9
4 COSM88262283 ZRSR2 lung,NS,carcinoma,small cell carcinoma c.1180G>A p.E394K 23:15822973-15822973 9
5 COSM97720347 ZRANB2 lung,NS,carcinoma,small cell carcinoma c.17T>C p.F6S 1:71080979-71080979 9
6 COSM137165710 ZP2 lung,NS,carcinoma,small cell carcinoma c.1608C>T p.P536= 16:21201455-21201455 9
7 COSM91416826 ZNF84 lung,NS,carcinoma,small cell carcinoma c.1024A>G p.T342A 12:133057739-133057739 9
8 COSM149927805 ZNF831 lung,NS,carcinoma,small cell carcinoma c.1027G>C p.D343H 20:59192046-59192046 9
9 COSM92021621 ZNF804B lung,NS,carcinoma,small cell carcinoma c.522C>A p.P174= 7:89333504-89333504 9
10 COSM92048538 ZNF804B lung,NS,carcinoma,small cell carcinoma c.3753G>C p.L1251= 7:89336735-89336735 9
11 COSM92024942 ZNF804B lung,NS,carcinoma,small cell carcinoma c.3661G>C p.A1221P 7:89336643-89336643 9
12 COSM88575001 ZNF804A lung,NS,carcinoma,small cell carcinoma c.862A>T p.K288* 2:184936258-184936258 9
13 COSM88576053 ZNF804A lung,NS,carcinoma,small cell carcinoma c.3281C>T p.S1094F 2:184938677-184938677 9
14 COSM84362584 ZNF777 lung,NS,carcinoma,small cell carcinoma c.1998C>T p.C666= 7:149432274-149432274 9
15 COSM114445791 ZNF746 lung,NS,carcinoma,small cell carcinoma c.890C>T p.A297V 7:149475432-149475432 9
16 COSM97007058 ZNF711 lung,NS,carcinoma,small cell carcinoma c.173A>T p.D58V 23:85255352-85255352 9
17 COSM97006621 ZNF711 lung,NS,carcinoma,small cell carcinoma c.1509G>T p.E503D 23:85270913-85270913 9
18 COSM110827987 ZNF7 lung,NS,carcinoma,small cell carcinoma c.1022G>C p.G341A 8:144842096-144842096 9
19 COSM122146768 ZNF667 lung,NS,carcinoma,small cell carcinoma c.132G>T p.L44F 19:56460717-56460717 9
20 COSM92174992 ZNF660 lung,NS,carcinoma,small cell carcinoma c.575G>A p.C192Y 3:44594768-44594768 9
21 COSM86006104 ZNF653 lung,NS,carcinoma,small cell carcinoma c.808C>T p.P270S 19:11487655-11487655 9
22 COSM86006115 ZNF653 lung,NS,carcinoma,small cell carcinoma c.346C>T p.R116W 19:11496163-11496163 9
23 COSM105713312 ZNF638 lung,NS,carcinoma,small cell carcinoma c.1926G>A p.K642= 2:71365637-71365637 9
24 COSM109858474 ZNF630 lung,NS,carcinoma,small cell carcinoma c.1534G>C p.E512Q 23:48058908-48058908 9
25 COSM90459483 ZNF609 lung,NS,carcinoma,small cell carcinoma c.1497C>T p.H499= 15:64674351-64674351 9
26 COSM87900489 ZNF608 lung,NS,carcinoma,small cell carcinoma c.3511C>T p.P1171S 5:124646873-124646873 9
27 COSM87898587 ZNF608 lung,NS,carcinoma,small cell carcinoma c.1722G>T p.Q574H 5:124648662-124648662 9
28 COSM87805997 ZNF574 lung,NS,carcinoma,small cell carcinoma c.860C>G p.S287C 19:42079196-42079196 9
29 COSM100923094 ZNF566 lung,NS,carcinoma,small cell carcinoma c.177G>T p.L59F 19:36472969-36472969 9
30 COSM91872428 ZNF536 lung,NS,carcinoma,small cell carcinoma c.1216C>A p.P406T 19:30444778-30444778 9
31 COSM91878766 ZNF536 lung,NS,carcinoma,small cell carcinoma c.3241C>A p.Q1081K 19:30548860-30548860 9
32 COSM91878758 ZNF536 lung,NS,carcinoma,small cell carcinoma c.383G>T p.R128L 19:30443945-30443945 9
33 COSM91871331 ZNF536 lung,NS,carcinoma,small cell carcinoma c.3646C>A p.Q1216K 19:30549265-30549265 9
34 COSM91884888 ZNF536 lung,NS,carcinoma,small cell carcinoma c.2185G>A p.A729T 19:30534861-30534861 9
35 COSM91873317 ZNF536 lung,NS,carcinoma,small cell carcinoma c.2259C>A p.C753* 19:30534935-30534935 9
36 COSM94775928 ZNF521 lung,NS,carcinoma,small cell carcinoma c.3289G>A p.V1097M 18:25224629-25224629 9
37 COSM94775934 ZNF521 lung,NS,carcinoma,small cell carcinoma c.2620G>T p.G874W 18:25225298-25225298 9
38 COSM94778877 ZNF521 lung,NS,carcinoma,small cell carcinoma c.3640G>T p.V1214F 18:25195178-25195178 9
39 COSM94791907 ZNF521 lung,NS,carcinoma,small cell carcinoma c.2227G>T p.V743L 18:25225691-25225691 9
40 COSM94774741 ZNF521 lung,NS,carcinoma,small cell carcinoma c.559G>C p.D187H 18:25227359-25227359 9
41 COSM91637929 ZNF512 lung,NS,carcinoma,small cell carcinoma c.698A>G p.D233G 2:27602491-27602491 9
42 COSM91851364 ZNF507 lung,NS,carcinoma,small cell carcinoma c.1899C>G p.Y633* 19:32354729-32354729 9
43 COSM91851246 ZNF507 lung,NS,carcinoma,small cell carcinoma c.1007C>G p.S336C 19:32353837-32353837 9
44 COSM90068876 ZNF479 lung,NS,carcinoma,small cell carcinoma c.1027C>T p.H343Y 7:57120388-57120388 9
45 COSM87572084 ZNF462 lung,NS,carcinoma,small cell carcinoma c.5136G>T p.L1712= 9:106929048-106929048 9
46 COSM91573770 ZNF444 lung,NS,carcinoma,small cell carcinoma c.239T>A p.V80E 19:56147150-56147150 9
47 COSM137384456 ZNF423 lung,NS,carcinoma,small cell carcinoma c.3329C>A p.P1110H 16:49635823-49635823 9
48 COSM137379733 ZNF423 lung,NS,carcinoma,small cell carcinoma c.1772T>G p.I591S 16:49637380-49637380 9
49 COSM137393174 ZNF423 lung,NS,carcinoma,small cell carcinoma c.146C>A p.T49K 16:49730902-49730902 9
50 COSM151538926 ZNF385B lung,NS,carcinoma,small cell carcinoma c.1381G>T p.A461S 2:179443285-179443285 9

Expression for Lung Non-Squamous Non-Small Cell Carcinoma

Search GEO for disease gene expression data for Lung Non-Squamous Non-Small Cell Carcinoma.

Pathways for Lung Non-Squamous Non-Small Cell Carcinoma

GO Terms for Lung Non-Squamous Non-Small Cell Carcinoma

Sources for Lung Non-Squamous Non-Small Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....